Botanix Pharmaceuticals Ltd (BOT) - Net Assets

Latest as of June 2025: AU$81.30 Million AUD

Based on the latest financial reports, Botanix Pharmaceuticals Ltd (BOT) has net assets worth AU$81.30 Million AUD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$129.10 Million) and total liabilities (AU$47.80 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$81.30 Million
% of Total Assets 62.98%
Annual Growth Rate 5.4%
5-Year Change 290.86%
10-Year Change 2455.84%
Growth Volatility 658.2

Botanix Pharmaceuticals Ltd - Net Assets Trend (1989–2025)

This chart illustrates how Botanix Pharmaceuticals Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Botanix Pharmaceuticals Ltd (1989–2025)

The table below shows the annual net assets of Botanix Pharmaceuticals Ltd from 1989 to 2025.

Year Net Assets Change
2025-06-30 AU$81.30 Million -25.23%
2024-06-30 AU$108.73 Million +373.76%
2023-06-30 AU$22.95 Million +181.55%
2022-06-30 AU$8.15 Million -60.81%
2021-06-30 AU$20.80 Million -12.00%
2020-06-30 AU$23.64 Million +3742.03%
2019-06-30 AU$615.22K -96.22%
2018-06-30 AU$16.28 Million +199.53%
2017-06-30 AU$5.44 Million +70.92%
2016-06-30 AU$3.18 Million +158.83%
2015-06-30 AU$1.23 Million -45.22%
2014-06-30 AU$2.24 Million +189.70%
2013-06-30 AU$-2.50 Million -7.18%
2012-06-30 AU$-2.33 Million -4.59%
2011-06-30 AU$-2.23 Million -24.19%
2010-06-30 AU$-1.80 Million -304.69%
2009-06-30 AU$877.74K -31.75%
2008-06-30 AU$1.29 Million -55.60%
2007-06-30 AU$2.90 Million +30.25%
2006-06-30 AU$2.22 Million -35.66%
2005-06-30 AU$3.46 Million +54.00%
2004-06-30 AU$2.24 Million -15.26%
2003-06-30 AU$2.65 Million -34.56%
2002-06-30 AU$4.05 Million -28.93%
2001-06-30 AU$5.69 Million +10.57%
2000-06-30 AU$5.15 Million -36.29%
1999-06-30 AU$8.08 Million -48.68%
1998-06-30 AU$15.75 Million -50.85%
1997-06-30 AU$32.05 Million -15.47%
1996-06-30 AU$37.91 Million -1.37%
1995-06-30 AU$38.44 Million +47.60%
1994-06-30 AU$26.04 Million +41.96%
1993-06-30 AU$18.35 Million +60.85%
1992-06-30 AU$11.41 Million -11.41%
1991-06-30 AU$12.88 Million +7.64%
1990-06-30 AU$11.96 Million -2.32%
1989-06-30 AU$12.24 Million --

Equity Component Analysis

This analysis shows how different components contribute to Botanix Pharmaceuticals Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 28450.1% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Common Stock AU$226.30 Million 278.36%
Other Comprehensive Income AU$32.18 Million 39.59%
Other Components AU$1.00 0.00%
Total Equity AU$81.30 Million 100.00%

Botanix Pharmaceuticals Ltd Competitors by Market Cap

The table below lists competitors of Botanix Pharmaceuticals Ltd ranked by their market capitalization.

Company Market Cap
Cassiar Gold Corp
V:GLDC
 		$51.60 Million
Pan Brothers Tbk
JK:PBRX
 		$51.61 Million
AdVini S.A.
PA:ALAVI
 		$51.63 Million
Rumble Resources Ltd
AU:RTR
 		$51.64 Million
Cheil Grinding
KO:001560
 		$51.59 Million
Asia Medical & Agricultural Laboratory & Research Center PCL
BK:AMARC
 		$51.58 Million
HORNG SHIUE HOLDING Co Ltd
TW:2243
 		$51.58 Million
Santova Ltd
JSE:SNV
 		$51.57 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Botanix Pharmaceuticals Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 108,732,549 to 81,298,929, a change of -27,433,620 (-25.2%).
  • Net loss of 86,396,186 reduced equity.
  • Share repurchases of 2,538,675 reduced equity.
  • New share issuances of 40,462,000 increased equity.
  • Other comprehensive income increased equity by 20,980,907.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AU$-86.40 Million -106.27%
Share Repurchases AU$2.54 Million -3.12%
Share Issuances AU$40.46 Million +49.77%
Other Comprehensive Income AU$20.98 Million +25.81%
Other Changes AU$58.33K +0.07%
Total Change AU$- -25.23%

Book Value vs Market Value Analysis

This analysis compares Botanix Pharmaceuticals Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.84x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has increased from 0.00x to 0.84x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1989-06-30 AU$15.75 AU$0.04 x
1990-06-30 AU$15.33 AU$0.04 x
1991-06-30 AU$16.51 AU$0.04 x
1992-06-30 AU$14.99 AU$0.04 x
1993-06-30 AU$16.93 AU$0.04 x
1994-06-30 AU$25.74 AU$0.04 x
1995-06-30 AU$48.76 AU$0.04 x
1996-06-30 AU$49.83 AU$0.04 x
1997-06-30 AU$42.12 AU$0.04 x
1998-06-30 AU$20.82 AU$0.04 x
1999-06-30 AU$32.32 AU$0.04 x
2000-06-30 AU$6.77 AU$0.04 x
2001-06-30 AU$14.96 AU$0.04 x
2002-06-30 AU$10.64 AU$0.04 x
2003-06-30 AU$6.96 AU$0.04 x
2004-06-30 AU$5.90 AU$0.04 x
2005-06-30 AU$12.40 AU$0.04 x
2006-06-30 AU$5.35 AU$0.04 x
2007-06-30 AU$6.20 AU$0.04 x
2008-06-30 AU$2.47 AU$0.04 x
2009-06-30 AU$1.54 AU$0.04 x
2010-06-30 AU$-0.28 AU$0.04 x
2011-06-30 AU$-0.33 AU$0.04 x
2012-06-30 AU$-0.61 AU$0.04 x
2013-06-30 AU$-0.59 AU$0.04 x
2014-06-30 AU$0.05 AU$0.04 x
2015-06-30 AU$0.01 AU$0.04 x
2016-06-30 AU$0.02 AU$0.04 x
2017-06-30 AU$0.01 AU$0.04 x
2018-06-30 AU$0.03 AU$0.04 x
2019-06-30 AU$0.00 AU$0.04 x
2020-06-30 AU$0.03 AU$0.04 x
2021-06-30 AU$0.02 AU$0.04 x
2022-06-30 AU$0.01 AU$0.04 x
2023-06-30 AU$0.02 AU$0.04 x
2024-06-30 AU$0.07 AU$0.04 x
2025-06-30 AU$0.04 AU$0.04 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Botanix Pharmaceuticals Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -106.27%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -1492.37%
  • • Asset Turnover: 0.04x
  • • Equity Multiplier: 1.59x
  • Recent ROE (-106.27%) is above the historical average (-129.81%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1989 -0.60% -0.38% 0.79x 2.01x AU$-1.27 Million
1990 -0.76% -0.42% 0.82x 2.19x AU$-1.26 Million
1991 -0.49% -0.24% 0.93x 2.18x AU$-1.32 Million
1993 -6.98% -2.72% 0.87x 2.95x AU$-2.19 Million
1994 -7.29% -3.17% 0.93x 2.48x AU$-3.39 Million
1995 -0.63% -0.35% 0.98x 1.84x AU$-3.94 Million
1997 0.41% 0.33% 0.81x 1.57x AU$-3.07 Million
1998 0.54% 0.00% 0.00x 1.92x AU$-1.50 Million
1999 -1.05% 0.00% 0.00x 2.00x AU$-893.40K
2000 -61.59% -34.69% 1.74x 1.02x AU$-3.69 Million
2001 -6.20% -68.02% 0.09x 1.03x AU$-922.47K
2002 -34.84% -381.72% 0.08x 1.11x AU$-1.81 Million
2003 -52.82% -151.18% 0.31x 1.11x AU$-1.66 Million
2004 -42.71% -209.52% 0.19x 1.08x AU$-1.18 Million
2005 0.06% 242.82% 0.00x 1.07x AU$-340.92K
2006 -125.09% -2991.40% 0.04x 1.13x AU$-3.00 Million
2007 -117.96% -6700.00% 0.01x 1.21x AU$-3.71 Million
2008 -219.66% -8071.43% 0.01x 1.84x AU$-2.95 Million
2009 -346.69% -33811.11% 0.00x 2.30x AU$-3.13 Million
2010 0.00% -198900.00% 0.02x 0.00x AU$-1.81 Million
2011 0.00% 0.00% 0.00x 0.00x AU$-1.30 Million
2012 0.00% 0.00% 0.00x 0.00x AU$-1.33 Million
2013 0.00% 0.00% 0.00x 0.00x AU$-1.60 Million
2014 -50.41% 0.00% 0.00x 1.14x AU$-1.36 Million
2015 -82.59% -2355.53% 0.03x 1.07x AU$-1.14 Million
2016 -53.70% 0.00% 0.00x 1.16x AU$-2.03 Million
2017 -87.79% -10264.52% 0.01x 1.09x AU$-5.32 Million
2018 -67.62% -619.35% 0.10x 1.09x AU$-12.64 Million
2019 -2769.60% -363.62% 0.90x 8.45x AU$-17.10 Million
2020 -70.78% -220.90% 0.30x 1.07x AU$-19.09 Million
2021 -16.03% -48.41% 0.31x 1.06x AU$-5.41 Million
2022 -161.57% -478.08% 0.20x 1.72x AU$-13.99 Million
2023 -39.88% -1000.47% 0.04x 1.08x AU$-11.45 Million
2024 -12.76% -2304.68% 0.01x 1.03x AU$-24.74 Million
2025 -106.27% -1492.37% 0.04x 1.59x AU$-94.53 Million

Industry Comparison

This section compares Botanix Pharmaceuticals Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $9,441,830
  • Average return on equity (ROE) among peers: -95.51%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Botanix Pharmaceuticals Ltd (BOT) AU$81.30 Million -0.60% 0.59x $51.59 Million
Adalta Ltd (1AD) $-598.24K 0.00% 0.00x $6.50 Million
Algorae Pharmaceuticals Ltd (1AI) $6.24 Million -90.94% 0.11x $17.18 Million
ACRUX Ltd (ACR) $9.09 Million -108.18% 0.68x $3.20 Million
Actinogen Medical Ltd (ACW) $346.99K -440.69% 0.34x $89.96 Million
Argenica Therapeutics Ltd (AGN) $8.31 Million -49.24% 0.09x $16.81 Million
Arovella Therapeutics Ltd (ALA) $8.84 Million -33.96% 0.88x $69.19 Million
Anatara Lifesciences Ltd (ANR) $1.36 Million -106.35% 0.22x $1.75 Million
Amplia Therapeutics Ltd (ATX) $15.84 Million -39.42% 0.18x $57.46 Million
Bio-Gene Technology Ltd (BGT) $2.79 Million -86.32% 0.13x $8.20 Million
Biotron Ltd (BIT) $42.20 Million 0.00% 0.00x $3.82 Million

About Botanix Pharmaceuticals Ltd

AU:BOT Australia Biotechnology
Market Cap
$51.59 Million
AU$72.91 Million AUD
Market Cap Rank
#24056 Global
#767 in Australia
Share Price
AU$0.04
Change (1 day)
-5.13%
52-Week Range
AU$0.04 - AU$0.47
All Time High
AU$0.52
Categories
Companies in Australia Biotechnology
About

Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment o… Read more